Academic Journal
Efficacy and Immunogenicity of Single-Dose AdVAV Intranasal Anthrax Vaccine Compared to Anthrax Vaccine Absorbed in an Aerosolized Spore Rabbit Challenge Model
| العنوان: | Efficacy and Immunogenicity of Single-Dose AdVAV Intranasal Anthrax Vaccine Compared to Anthrax Vaccine Absorbed in an Aerosolized Spore Rabbit Challenge Model |
|---|---|
| المؤلفون: | Krishnan, Vyjayanthi, Andersen, Bo H., Shoemaker, Christine, Sivko, Gloria S., Tordoff, Kevin P., Stark, Gregory V., Zhang, Jianfeng, Feng, Tsungwei, Duchars, Matthew, Roberts, M. Scot |
| المساهمون: | Pasetti, M. F. |
| المصدر: | Clinical and Vaccine Immunology ; volume 22, issue 4, page 430-439 ; ISSN 1556-6811 1556-679X |
| بيانات النشر: | American Society for Microbiology |
| سنة النشر: | 2015 |
| الوصف: | AdVAV is a replication-deficient adenovirus type 5-vectored vaccine expressing the 83-kDa protective antigen (PA83) from Bacillus anthracis that is being developed for the prevention of disease caused by inhalation of aerosolized B. anthracis spores. A noninferiority study comparing the efficacy of AdVAV to the currently licensed Anthrax Vaccine Absorbed (AVA; BioThrax) was performed in New Zealand White rabbits using postchallenge survival as the study endpoint (20% noninferiority margin for survival). Three groups of 32 rabbits were vaccinated with a single intranasal dose of AdVAV (7.5 × 10 7 , 1.5 × 10 9 , or 3.5 × 10 10 viral particles). Three additional groups of 32 animals received two doses of either intranasal AdVAV (3.5 × 10 10 viral particles) or intramuscular AVA (diluted 1:16 or 1:64) 28 days apart. The placebo group of 16 rabbits received a single intranasal dose of AdVAV formulation buffer. All animals were challenged via the inhalation route with a targeted dose of 200 times the 50% lethal dose (LD 50 ) of aerosolized B. anthracis Ames spores 70 days after the initial vaccination and were followed for 3 weeks. PA83 immunogenicity was evaluated by validated toxin neutralizing antibody and serum anti-PA83 IgG enzyme-linked immunosorbent assays (ELISAs). All animals in the placebo cohort died from the challenge. Three of the four AdVAV dose cohorts tested, including two single-dose cohorts, achieved statistical noninferiority relative to the AVA comparator group, with survival rates between 97% and 100%. Vaccination with AdVAV also produced antibody titers with earlier onset and greater persistence than vaccination with AVA. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| DOI: | 10.1128/cvi.00690-14 |
| DOI: | 10.1128/CVI.00690-14 |
| الاتاحة: | http://dx.doi.org/10.1128/cvi.00690-14 https://syndication.highwire.org/content/doi/10.1128/CVI.00690-14 |
| رقم الانضمام: | edsbas.70528C4A |
| قاعدة البيانات: | BASE |
| DOI: | 10.1128/cvi.00690-14 |
|---|